Literature DB >> 22407872

A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells.

Sepideh Khaleghi1, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Mohammad J Rasaee, Philippe Pognonec.   

Abstract

In accordance with the two-step hypothesis of T cell activation and the observation that stimulation through the T cell receptor (TCR) alone may lead to anergy, we focused on the introduction of co-stimulatory signaling to this type of receptors to achieve optimal activation. Enhanced mRNA and cell surface receptor expression via the co-stimulatory gene fragment (OX40) was confirmed by RT-PCR and flow cytometry. Inclusion of the OX40 co-stimulatory signaling region in series with the TCR led to enhanced antigen-induced IL-2 production after stimulation by MUC1-expressing cancer cell lines as compared to the chimeric receptor without OX40. Moreover, with the aim of maintaining high efficiency, while providing a means of controlling any possible unwanted proliferation in vivo, a regulation system was used. This controls the dimerization of a membrane-bound caspase 8 protein. Toward that goal, pFKC8 and CAR constructs were co-transfected into Jurkat cells, and the level of apoptosis was measured. 24 h after addition of the dimerizer, a 91% decrease in transfected cells was observed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407872     DOI: 10.1007/s12185-012-1037-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  38 in total

1.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Authors:  F A Harding; J G McArthur; J A Gross; D H Raulet; J P Allison
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

2.  Development of an inducible suicide gene system based on human caspase 8.

Authors:  Françoise Carlotti; Arnaud Zaldumbide; Patrick Martin; Kim E Boulukos; Rob C Hoeben; Philippe Pognonec
Journal:  Cancer Gene Ther       Date:  2005-07       Impact factor: 5.987

3.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

Authors:  Martin A Pulè; Karin C Straathof; Gianpietro Dotti; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner
Journal:  Mol Ther       Date:  2005-06-23       Impact factor: 11.454

4.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Authors:  T Clackson; W Yang; L W Rozamus; M Hatada; J F Amara; C T Rollins; L F Stevenson; S R Magari; S A Wood; N L Courage; X Lu; F Cerasoli; M Gilman; D A Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

5.  High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli.

Authors:  Fatemeh Rahbarizadeh; Mohammad Javad Rasaee; Mehdi Forouzandeh-Moghadam; Abdol-Amir Allameh
Journal:  Protein Expr Purif       Date:  2005-11       Impact factor: 1.650

6.  Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.

Authors:  Agnes S Y Lo; Qiangzhong Ma; David L Liu; Richard P Junghans
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

7.  Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization.

Authors:  D M Spencer; P J Belshaw; L Chen; S N Ho; F Randazzo; G R Crabtree; S L Schreiber
Journal:  Curr Biol       Date:  1996-07-01       Impact factor: 10.834

8.  Synthetic activation of caspases: artificial death switches.

Authors:  R A MacCorkle; K W Freeman; D M Spencer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.

Authors:  Helene M Finney; Arne N Akbar; Alastair D G Lawson
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

View more
  16 in total

1.  Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.

Authors:  Yushu Joy Xie; Michael Dougan; Noor Jailkhani; Jessica Ingram; Tao Fang; Laura Kummer; Noor Momin; Novalia Pishesha; Steffen Rickelt; Richard O Hynes; Hidde Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

Review 2.  How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Authors:  Albert T Gacerez; Benjamine Arellano; Charles L Sentman
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

Review 3.  CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Med       Date:  2022-06-10       Impact factor: 9.927

Review 4.  Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.

Authors:  Corey Falcon; Mustafa Al-Obaidi; Antonio Di Stasi
Journal:  Biomedicines       Date:  2017-06-14

Review 5.  Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.

Authors:  Yelei Guo; Kaichao Feng; Yao Wang; Weidong Han
Journal:  Protein Cell       Date:  2017-03-13       Impact factor: 14.870

6.  Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.

Authors:  Haibo Han; Shanshan Wang; Ying Hu; Zhaowei Li; Wei Yang; Yunwei Lv; Limin Wang; Lianhai Zhang; Jiafu Ji
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

Review 7.  Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.

Authors:  Yelei Guo; Yao Wang; Weidong Han
Journal:  J Immunol Res       Date:  2016-02-21       Impact factor: 4.818

Review 8.  Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.

Authors:  Peter Bannas; Julia Hambach; Friedrich Koch-Nolte
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

Review 9.  Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.

Authors:  Lichen Zhu; Xiaomei Yang; Dani Zhong; Shenxia Xie; Wei Shi; Yangzi Li; Xiaoqiong Hou; Huihui Zhou; Minlong Zhao; Ziqiang Ding; Xinyue Zhao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  J Immunol Res       Date:  2020-09-07       Impact factor: 4.818

10.  Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

Authors:  Mahmoud Hassani; Fatemeh Hajari Taheri; Zahra Sharifzadeh; Arash Arashkia; Jamshid Hadjati; Wytske M. van Weerden; Shahriyar Abdoli; Mohammad Hossein Modarressi; Mohsen Abolhassani
Journal:  Iran Biomed J       Date:  2019-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.